MY ACCOUNT | NEWSLETTER |

Xylazine Infusion during Equine Colic Anesthesia with Isoflurane and Lidocaine: A Retrospective Study


Equine colic is a critical and painful illness. Xylazine provides analgesia; sedation and muscle relaxation; and improves anesthetic recoveries in healthy horses. These might be useful for anesthesia in colic patients. This study aimed to retrospectively evaluate the intraoperative effects, and the influence on recovery from anesthesia, of adding a xylazine infusion (group XL) to isoflurane and lidocaine infusion (group L) for anesthesia maintenance. Cardiovascular parameters, blood gas analyses, anesthetic requirements, and time during recovery were retrospectively studied. Minimal and average heart rate, hematocrit, ketamine requirements and days to discharge were significantly lower in group XL than in group L. Time to sternal and first attempt to stand were significantly longer in group XL than in group L. Group XL showed almost twice the number of ‘best possible’ recoveries and no horses with the worst score. The reductions in heart rate and hematocrit were considered clinically irrelevant. The time to finally stand remained similar in both groups. Xylazine infusion might provide a stable anesthesia since less animals required ketamine. Animals in this group went home sooner and none of them had a dangerous recovery. Xylazine infusion might be a good option for anesthesia maintenance in colic patients.

A xylazine infusion during partial intravenous equine colic anesthesia with isoflurane and lidocaine was associated with fewer intraoperative ketamine boluses and earlier hospital discharge. It was associated with an increment in the time in lateral recumbency and a delay in the first attempt to stand, but not with a longer time to finally stand. Xylazine infusion during colic anesthesia with isoflurane and lidocaine was associated with almost twice as many excellent recoveries compared to the infusion of only lidocaine with a xylazine bolus for recovery. The intraoperative heart rate and hematocrit reduction were clinically irrelevant.

Balanced anesthesia and the administration of co-drugs has long been promoted, but today we realize that we do not know what the interactions are between these molecules, which is why we must be extremely cautious; observations concerning the administration of several molecules must be supported by strong evidence. Further prospective studies are warranted to confirm the results found in this retrospective study.


Authors: Patricia Ruíz-López, Charlotte Cuypers, Stijn Schauvliege
Source: https://www.mdpi.com/2076-2615/13/18/2902

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Feline pemphigus foliaceus: a retrospective analysis of 57 cases

Like0
Dislike0

Clinical Case of a Transfusion-Associated Canine Mycoplasma haemocanis Infection in the Republic of Korea: A Case Report

Like0
Dislike0

Review of Nonfoodborne Zoonotic and Potentially Zoonotic Poultry Diseases

Like0
Dislike0

Solving Medical Mysteries: Dr. Philip Kass Delivers 2025 Oscar W. Schalm Lecture

Like0
Dislike0

Chewy to Acquire SmartEquine, Expanding Leadership in the Equine Health Category

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top